Avenue Therapeutics, Inc. Made Big Gain
Thu, Jan 04, 2024 at 07:47 PM
Avenue Therapeutics, Inc. (ATXI:NASDAQ) soared at $0.34, a gain of 94.5%. On Thu, Jan 04, 2024, ATXI:NASDAQ touched a New 2-Week High of $0.34. The stock appeared on our News Catalysts scanner on Thu, Jan 04, 2024 at 10:06 AM in the 'AGREEMENT' category. From Thu, Dec 21, 2023, the stock recorded 37.50% Up Days and 44.44% Green Days
About Avenue Therapeutics, Inc. (ATXI:NASDAQ)
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of an intravenous, or IV, formulation of tramadol HCl, or IV Tramadol, for the management of moderate to moderately severe postoperative pain.
Top 10 Gainers:
- Omega Therapeutics Inc. (OMGA:NASDAQ), 94.69%
- Avenue Therapeutics, Inc. (ATXI:NASDAQ), 94.49%
- KORE Group Holdings Inc. (KORE:NYSE), 60.53%
- Alaunos Therapeutics Inc Com (TCRT:NASDAQ), 56.21%
- Mobix Labs Inc. (MOBX:NASDAQ), 45.33%
- QuantumScape Corporation Class A (QS:NYSE), 43.08%
- Mountain Crest Acquisition Corp. IV (MCAF:NASDAQ), 40.94%
- Isoray. (DE) (CATX:NYSEMKT), 37.02%
- Comera Life Sciences Holdings Inc. (CMRA:NASDAQ), 34.81%
- Top KingWin Ltd (TCJH:NASDAQ), 33.11%